Injection technology company PharmaJet revealed on Tuesday that its Needle-free Injection System (NFIS) will be used in a clinical trial that will deliver a booster vaccine against COVID-19 virus variants.
The vaccine is reportedly developed by DIOSynVax, a spinoff company supported by the University of Cambridge in the UK,
Under the University of Cambridge's Phase 1 clinical trial, the COVID-19 vaccine will be delivered exclusively with the PharmaJet Tropis Needle-free injection system, which was selected based on its ability to increase the efficacy of nucleic acid-based vaccines and therapeutics.
This is the 20th COVID-19 vaccine development programme using PharmaJet Needle-free Injection Systems as their method of delivery.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval